Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study

Advances in Medical Sciences
Fedor HlebokazovSergei Marchuk

Abstract

Existing anti-epileptic drugs (AED) have limited efficiency in many patients, necessitating the search for alternative approaches such as stem cell therapy. We report the use of autologous patient-derived mesenchymal stem cells (MSC) as a therapeutic agent in symptomatic drug-resistant epilepsy in a Phase I open label clinical trial (registered as NCT02497443). The patients received either standard treatment with AED (control group), or AED supplemented with single intravenous administration of undifferentiated autologous MSC (target dose of 1×106cells/kg), followed by a single intrathecal injection of neurally induced autologous MSC (target dose of 0.1×106cells/kg). MSC injections were well tolerated and did not cause any severe adverse effects. Seizure frequency was designated as the main outcome and evaluated at 1 year time point. 3 out of 10 patients in MSC therapy group achieved remission (no seizures for one year and more), and 5 additional patients became responders to AEDs, while only 2 out of 12 patients became responders in control group (difference significant, P=0.0135). MSC possess unique immunomodulatory properties and are a safe and promising candidate for cell therapy in AED resistant epilepsy patients.

Associated Clinical Trials

Jul 14, 2015·Potapnev Michael, MD, Prof.

Citations

May 28, 2019·International Journal of Molecular Sciences·Loubna MaziniGabriel Malka
Feb 14, 2020·The International Journal of Neuroscience·Ali A Asadi-Pooya, Luca Bartolini
Jun 24, 2020·Stem Cells Translational Medicine·Bogna BadyraMarcin Majka
Dec 18, 2018·Frontiers in Neurology·Clarissa F CavarsanLuciene Covolan
Aug 9, 2020·Frontiers in Cell and Developmental Biology·Matthew H ForsbergChristian M Capitini
Aug 17, 2019·Frontiers in Immunology·Henry CaplanCharles S Cox
Dec 19, 2020·Clinical Neurology and Neurosurgery·Hadi AligholiAli A Asadi-Pooya
Jan 6, 2021·Cytokine & Growth Factor Reviews·Inês BarrosCatarina Oliveira Miranda
Jun 14, 2021·Clinical Neurology and Neurosurgery·Fedor HlebokazovNatalia Goncharova
Jul 1, 2020·Current Stem Cell Research & Therapy·Tahereh EbrahimiSoheila Montazersaheb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.